Year-long clenbuterol treatment of mice increases mass, but not specific force or normalized power, of skeletal muscles.
نویسندگان
چکیده
1. Clenbuterol has been proposed for the treatment of muscle wasting disorders, but its long-term effects on skeletal muscle function have not been tested rigorously. We tested the hypothesis that year-long treatment of young (6 months) mice with clenbuterol would increase skeletal muscle mass and in vitro measurements of specific force (Po) and power output. 2. Male mice (C57BL/10ScSn) were divided into treated (n = 6) or untreated (n = 8) groups. Treated mice received clenbuterol (1.5-2 mg/kg per day) in their drinking water for 52 weeks, following a staggered 3 day on/3 day off schedule to attenuate the response to clenbuterol. 3. Clenbuterol treatment increased the absolute mass of each muscle tested: the heart by 28%, extensor digitorum longus (EDL) by 16%, soleus by 22% and tibialis anterior by 17%. For treated compared with untreated mice, absolute Po (mN) was greater in soleus muscles but not different in EDL muscles. Absolute power output (mW) of the EDL and soleus muscles was not different and no differences were observed for the specific Po (kN/m2) or normalized power output (W/kg) of EDL muscles, soleus muscles or diaphragm muscle strips. 4. We conclude that, following year-long treatment of mice with clenbuterol, the mass of the heart and both fast and slow skeletal muscles is increased, but the lack of any change in normalized Po or power output indicates that clenbuterol has little therapeutic effect on the functional properties of skeletal muscle.
منابع مشابه
Power output of fast and slow skeletal muscles of mdx (dystrophic) and control mice after clenbuterol treatment.
The mdx mouse is the most commonly used animal model for Duchenne muscular dystrophy. We tested the null hypothesis that 20 weeks of clenbuterol treatment ( approximately 2 mg kg-1 day-1) of mdx and control mice would have no effect on the absolute and specific force (Po, kN m-2) and absolute and normalised power output (W kg-1) of extensor digitorum longus (EDL) and soleus muscles. For mdx and...
متن کاملAlteration of contractile force and mass in the senescent diaphragm with beta(2)-agonist treatment.
Aging is associated with a decrease in diaphragmatic maximal tetanic force production (P(o)) in senescent rats. Treatment with the beta(2)-agonist clenbuterol (CB) has been shown to increase skeletal muscle mass and P(o) in weak locomotor skeletal muscles from dystrophic rodents. It is unknown whether CB can increase diaphragmatic mass and P(o) in senescent rats. Therefore, we tested the hypoth...
متن کاملEffects of Chronic Administration of Clenbuterol on Contractile Properties and Calcium Homeostasis in Rat Extensor Digitorum Longus Muscle
Clenbuterol, a β2-agonist, induces skeletal muscle hypertrophy and a shift from slow-oxidative to fast-glycolytic muscle fiber type profile. However, the cellular mechanisms of the effects of chronic clenbuterol administration on skeletal muscle are not completely understood. As the intracellular Ca2+ concentration must be finely regulated in many cellular processes, the aim of this study was t...
متن کاملA physiological level of clenbuterol does not prevent atrophy or loss of force in skeletal muscle of old rats.
Supraphysiological levels of clenbuterol (CL) reduce muscle degradation in both young and old animals; however, these pharmacological levels induce side effects that are unacceptable in the elderly. In this study, we tested the hypothesis that a "physiological" dose of CL (10 microg. kg(-1). day(-1)) would attenuate the loss of in situ isometric force and mass in muscles of senescent rats durin...
متن کامل2-Agonist fenoterol has greater effects on contractile function of rat skeletal muscles than clenbuterol
Ryall, James G., Paul Gregorevic, David R. Plant, Martin N. Sillence, and Gordon S. Lynch. 2-Agonist fenoterol has greater effects on contractile function of rat skeletal muscles than clenbuterol. Am J Physiol Regul Integr Comp Physiol 283: R1386–R1394, 2002. First published September 5, 2002; 10.1152/ajpregu.00324.2002.—Potential treatments for skeletal muscle wasting and weakness ideally poss...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Clinical and experimental pharmacology & physiology
دوره 26 2 شماره
صفحات -
تاریخ انتشار 1999